Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?

References

• PolmanCHO’ConnorPWHavrdovaEA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisN Engl J Med2006354989991016510744
   PubMed Web of Science ®Google Scholar
• RudickRAStuartWHCalabresiPANatalizumab plus interferon beta-1a for relapsing multiple sclerosisN Engl J Med2006354991192316510745
   PubMed Web of Science ®Google Scholar
• BloomgrenGRichmanSHotermansCRisk of natalizumab-associated progressive multifocal leukoencephalopathyN Engl J Med2012366201870188022591293
   PubMed Web of Science ®Google Scholar
• GorelikLLernerMBixlerSAnti-JC virus antibodies: implications for PML risk stratificationAnn Neurol201068329530320737510
   PubMed Web of Science ®Google Scholar
• BozicCRichmanSPlavinaTAnti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1Ann Neurol201170574275022162056
   PubMed Web of Science ®Google Scholar
• TrampeAKHemmelmannCStroetAAnti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohortNeurology201278221736174222592369
   PubMed Web of Science ®Google Scholar
• PlavinaTLeeSBermanMLongitudinal stability of anti-JC virus antibody status in multiple sclerosis patients: results of STRATIFY-1 (S30.001)Neurology201380Meeting Abstracts 1S.30.001
   Google Scholar
• DerfussTKuhleJLindbergRKapposLNatalizumab therapy for multiple sclerosisSemin Neurol2013331263623709210
   PubMed Web of Science ®Google Scholar
• BlairNFBrewBJHalpernJPNatalizumab-associated PML identified in the presymptomatic phase using MRI surveillanceNeurology201278750750822302545
   PubMed Web of Science ®Google Scholar
• YousryTAPelletierDCadavidDMagnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathyAnn Neurol201272577978723280794
   PubMed Web of Science ®Google Scholar
• KrumbholzMPellkoferHGoldRHoffmannLAHohlfeldRKumpfelTDelayed allergic reaction to natalizumab associated with early formation of neutralizing antibodiesArch Neurol20076491331133317846274
   PubMedGoogle Scholar
• SorensenPSJensenPEHaghikiaAOccurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumabMult Scler20111791074107821511692
   PubMed Web of Science ®Google Scholar
• OliverBFernandezOOrpezTKinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 monthsMult Scler201117336837121177326
   PubMed Web of Science ®Google Scholar
• Oliver-MartosBOrpez-ZafraTUrbanejaPMaldonado-SanchezRLeyvaLFernandezOEarly development of anti-natalizumab antibodies in MS patientsJ Neurol2013614 Epub ahead of print
   PubMed Web of Science ®Google Scholar
• AbbasMLalivePHChofflonMSimonHUChizzoliniCRibiCHypereosinophilia in patients with multiple sclerosis treated with natalizumabNeurology201177161561156421975205
   PubMed Web of Science ®Google Scholar
• SchweikertAKremerMRingelFPrimary central nervous system lymphoma in a patient treated with natalizumabAnn Neurol200966340340619798640
   PubMed Web of Science ®Google Scholar
• RansohoffRMNatalizumab, multiple sclerosis, and primary central nervous system lymphoma: enigma, wrapped in mystery, enclosed in conundrumAnn Neurol200966325926119798722
   PubMed Web of Science ®Google Scholar
• SchowinskyJCorboyJVollmerTKleinschmidt-DeMastersBKNatalizumab-associated complication? First case of peripheral T cell lymphomaActa Neuropath2012123575175222407011
   PubMed Web of Science ®Google Scholar
• MullenJTVartanianTKAtkinsMBMelanoma complicating treatment with natalizumab for multiple sclerosisN Engl J Med2008358664764818256405
   PubMed Web of Science ®Google Scholar
• PanzaraMABozicCSandrockAWMore on melanoma with transdifferentiationN Engl J Med2008359199 author reply 99–10018596284
   PubMed Web of Science ®Google Scholar
• CastelaELebrun-FrenayCLaffonMEvolution of nevi during treatment with natalizumab: A prospective follow-up of patients treated with natalizumab for multiple sclerosisArch Dermatol20111471727620855675
   PubMedGoogle Scholar
• LeussinkVILehmannHCMeyer zu HorsteGHartungHPStuveOKieseierBCRituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneityJ Neurol200825591436143818685916
   PubMed Web of Science ®Google Scholar
• HellwigKHaghikiaAGoldRPregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatmentMult Scler201117895896321613333
   PubMed Web of Science ®Google Scholar
• StuveOMarraCMJeromeKRImmune surveillance in multiple sclerosis patients treated with natalizumabAnn Neurol200659574374716634029
   PubMed Web of Science ®Google Scholar
• VellingaMMCastelijnsJABarkhofFUitdehaagBMPolmanCHPostwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patientsNeurology20087013 Pt 21150115117872364
   PubMed Web of Science ®Google Scholar
• StuveOCravensPDFrohmanEMImmunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapyNeurology200972539640118987352
   PubMed Web of Science ®Google Scholar
• CreeBDe SezeJFoxRNatalizumab effects during a 6-month dose Interruption: relationship of pharmacokinetic (PK), pharmacodynamic (PD), and MRI measurements (S41.003)Neurology201380Meeting Abstracts 1S.41.003
   Google Scholar
• HavlaJGerdesLAMeinlIDe-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetateJ Neurol201125891665166921431380
   PubMed Web of Science ®Google Scholar
• O’ConnorPWGoodmanAKapposLDisease activity return during natalizumab treatment interruption in patients with multiple sclerosisNeurology201176221858186521543733
   PubMed Web of Science ®Google Scholar
• KapposLBatesDEdanGNatalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoringLancet Neurol201110874575821777829
   PubMed Web of Science ®Google Scholar
• KillesteinJVennegoorAStrijbisEMNatalizumab drug holiday in multiple sclerosis: poorly toleratedAnn Neurol201068339239520661928
   PubMed Web of Science ®Google Scholar
• RigauVManiaABefortPLethal multiple sclerosis relapse after natalizumab withdrawalNeurology201279222214221623100404
   PubMed Web of Science ®Google Scholar
• FoxRKapposLCreeBEffects of a 24-week natalizumab treatment interruption on clinical and radiologic parameters of multiple sclerosis disease activity: the RESTORE study5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple SclerosisOctober 19–22, 2011Amsterdam, The Netherlands
   Google Scholar
• ClericoMDe MercantiSPiazzaFNatalizumab discontinuation after the 24th course: which is way? The TY-STOP Study (P01.197)Neurology201380Meeting Abstracts 1P01.197
   Google Scholar
• LenhardTBillerAMuellerWMetzISchonbergerJWildemannBImmune reconstitution inflammatory syndrome after withdrawal of natalizumab?Neurology201075983183320805529
   PubMed Web of Science ®Google Scholar
• MiravalleAJensenRKinkelRPImmune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapyArch Neurol201168218619120937940
   PubMedGoogle Scholar
• PapeixCDepazRTourbahAStankoffBLubetzkiCDramatic worsening following plasma exchange in severe post-natalizumab withdrawal multiple sclerosis relapseMult Scler201117121520152221669937
   PubMed Web of Science ®Google Scholar
• BorrielloGProsperiniLMancinelliCGianniCFubelliFPozzilliCPulse monthly steroids during an elective interruption of natalizumab: a post-marketing studyEur J Neurol201219578378722054236
   PubMed Web of Science ®Google Scholar
• MagranerMJCoretFNavarreAPulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational studyJ Neurol2011258101805181121625938
   PubMed Web of Science ®Google Scholar
• GobbiCMeierDSCottonFInterferon beta 1b following natalizumab discontinuation: one year, randomized, prospective, pilot trialBMC Neurol20131310123915113
   PubMed Web of Science ®Google Scholar
• RossiSMottaCStuderVEffect of glatiramer acetate on disease reactivation in MS patients discontinuing natalizumabEur J Neurol2013201879422741530
   PubMed Web of Science ®Google Scholar
• KapposLRadueEWO’ConnorPA placebo-controlled trial of oral fingolimod in relapsing multiple sclerosisN Engl J Med2010362538740120089952
   PubMed Web of Science ®Google Scholar
• CohenJABarkhofFComiGOral fingolimod or intramuscular interferon for relapsing multiple sclerosisN Engl J Mws20103625402415
   PubMed Web of Science ®Google Scholar
• HavlaJBPellkoferHLMeinlIGerdesLAHohlfeldRKumpfelTRebound of disease activity after withdrawal of fingolimod (FTY720) treatmentArch Neurol201269226226422332194
   PubMedGoogle Scholar
• LysandropoulosAPBenghiatFSevere auto-immune hemolytic anemia in a fingolimod-treated multiple sclerosis patientMult Scler201371 Epub ahead of print
   Web of Science ®Google Scholar
• GrossCMBaumgartnerARauerSStichOMultiple sclerosis rebound following herpes zoster infection and suspension of fingolimodNeurology201279192006200723035074
   PubMed Web of Science ®Google Scholar
• RatchfordJNCostelloKReichDSCalabresiPAVaricella-zoster virus encephalitis and vasculopathy in a patient treated with fingolimodNeurology201279192002200423035072
   PubMed Web of Science ®Google Scholar
• VisserFWattjesMPPouwelsPJLinssenWHvan OostenBWTumefactive multiple sclerosis lesions under fingolimod treatmentNeurology201279192000200323035065
   PubMed Web of Science ®Google Scholar
• HavlaJTackenbergBHellwigKFingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosisJ Neurol201326051382138723266894
   PubMed Web of Science ®Google Scholar
• RinaldiFSeppiDCalabreseMPeriniPGalloPSwitching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findingsMult Scler201218111640164323100526
   PubMed Web of Science ®Google Scholar
• LaroniABrogiDMilesiVAbateLUccelliAMancardiGEarly switch to fingolimod may decrease the risk of disease recurrence after natalizumab interruptionMult Scler20131991236123723184503
   PubMed Web of Science ®Google Scholar
• CentonzeDRossiSRinaldiFGalloPSevere relapses under fingolimod treatment prescribed after natalizumabNeurology201279192004200523035063
   PubMed Web of Science ®Google Scholar
• CastropFKowarikMCAlbrechtHSevere multiple sclerosis relapse under fingolimod therapy: incident or coincidence?Neurology2012781292893022402856
   PubMed Web of Science ®Google Scholar
• DaelmanLMaitrotAMaaroufAChaunuMPapeixCTourbahASevere multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawalMult Scler201218111647164922907938
   PubMed Web of Science ®Google Scholar
• JanderSTurowskiBKieseierBCHartungHPEmerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimodMult Scler201218111650165223100527
   PubMed Web of Science ®Google Scholar
• ComiGGoldRDahlkeFRelapse outcomes in fingolimod-treated patients previously exposed to natalizumab: post-hoc analysis from the 4-month, open-label FIRST study (P07.103)Neurology201380Meeting Abstracts 1P07.103
   Google Scholar
• CohenMMaillartEPapeixCENIGM: A French observational study about switching from natalizumab to fingolimod in multiple sclerosis (S41.002)Neurology201380Meeting Abstracts 1S41.00223479543
   PubMed Web of Science ®Google Scholar
• O’ConnorPWolinskyJSConfavreuxCRandomized trial of oral teriflunomide for relapsing multiple sclerosisN Engl J Med2011365141293130321991951
   PubMed Web of Science ®Google Scholar
• PhillipsJTFoxRJBG-12 in multiple sclerosisSem Neurol20133315665
   PubMed Web of Science ®Google Scholar
• FoxRJMillerDHPhillipsJTPlacebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosisN Engl J Med2012367121087109722992072
   PubMed Web of Science ®Google Scholar
• GoldRKapposLArnoldDLPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisN Engl J Med2012367121098110722992073
   PubMed Web of Science ®Google Scholar
• van OostenBWKillesteinJBarkhofFPolmanCHWattjesMPPML in a patient treated with dimethyl fumarate from a compounding pharmacyN Engl J Med2013368171658165923614604
   PubMed Web of Science ®Google Scholar
• SweetserMTDawsonKTBozicCManufacturer’s response to case reports of PMLN Engl J Med2013368171659166123614605
   PubMed Web of Science ®Google Scholar
• ErmisUWeisJSchulzJBPML in a patient treated with fumaric acidN Engl J Med2013368171657165823614603
   PubMed Web of Science ®Google Scholar
• CohenJAColesAJArnoldDLAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialLancet201238098561819182823122652
   PubMed Web of Science ®Google Scholar
• ColesAJTwymanCLArnoldDLAlemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trialLancet201238098561829183923122650
   PubMed Web of Science ®Google Scholar
• ColesAJAlemtuzumab treatment of multiple sclerosisSem Neurol20133316673
   PubMed Web of Science ®Google Scholar
• KaufmanMDLeeRNortonHCourse of relapsing-remitting multiple sclerosis before, during and after natalizumabMult Scler201117449049421135017
   PubMed Web of Science ®Google Scholar
• HauserSLWaubantEArnoldDLB-cell depletion with rituximab in relapsing-remitting multiple sclerosisN Engl J Med2008358767668818272891
   PubMed Web of Science ®Google Scholar
• StuveOLeussinkVIFrohlichRLong-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosisArch Neurol200966225926119204165
   PubMedGoogle Scholar